Scinovex
reviewTop 1% cited

Risk of first‐generation H<sub>1</sub>‐antihistamines: a GA<sup>2</sup>LEN position paper

Allergy · 2010 · Vol. 65(4) · pp. 459–466
Martin K. ChurchMarcus MaurerF. Estelle R. SimonsCarsten Bindslev‐JensenPaul Van CauwenbergeJean BousquetStephen T. HolgateTorsten Zuberbier

Abstract

This review raises the issue of better consumer protection by recommending that older first-generation H(1)-antihistamines should no longer be available over-the-counter as prescription- free drugs for self-medication of allergic and other diseases now that newer second- generation nonsedating H(1)-antihistamines with superior risk/benefit ratios are widely available at competitive prices.

Asthma and respiratory diseasesAllergic Rhinitis and SensitizationFood Allergy and Anaphylaxis ResearchMedicineMedical prescriptionPublic healthAsthmaOver-the-counterMedical emergencyAuditFamily medicinePediatricsPsychiatry

MeSH terms

BrainCognitionNonprescription DrugsHistamine H1 AntagonistsHumansHypersensitivityUnited StatesDrug Approval
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Risk of first‐generation H<sub>1</sub>‐antihistamines: a GA<sup>2</sup>LEN position paper · Scinovex